These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 18222957

  • 1. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A, Johnson E, Hockey H, Troke P.
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [Abstract] [Full Text] [Related]

  • 2. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [Abstract] [Full Text] [Related]

  • 3. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A.
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [Abstract] [Full Text] [Related]

  • 5. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE, Wiederhold NP, Klepser ME.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM, Szekely A, Warnock DW.
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [Abstract] [Full Text] [Related]

  • 11. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P.
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.
    Wildfeuer A, Seidl HP, Paule I, Haberreiter A.
    Mycoses; 1998 Sep; 41(7-8):309-19. PubMed ID: 9861837
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E, Pemán J, Valverde A, Chaves M, Serrano MC, Cantón E.
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
    Wang HC, Hsieh MI, Choi PC, Wu CJ.
    J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
    [Abstract] [Full Text] [Related]

  • 18. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
    Marco F, Pfaller MA, Messer SA, Jones RN.
    Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
    [Abstract] [Full Text] [Related]

  • 19. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
    Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH.
    J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
    [Abstract] [Full Text] [Related]

  • 20. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group.
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.